TWO CYCLES OF TPF AS INDUCTION CHEMOTHERAPY IN LOCALLY ADVANCED HEAD-AND-NECK SQUAMOUS CELL CANCER FOR INDIAN PATIENTS: CAN LESS BE MORE?

ANVITA BHATI; RAMESH PUROHIT; AJAY KUMAR YADAV; SHASHANK KOTHARI

doi:10.22159/ajpcr.2025v18i3.53921

Authors

ANVITA BHATI Department of Radiation Oncology, Geetanjali Medical College and Hospital, Udaipur, Rajasthan, India
RAMESH PUROHIT Department of Radiation Oncology, Geetanjali Medical College and Hospital, Udaipur, Rajasthan, India
AJAY KUMAR YADAV Department of Surgical Oncology, Geetanjali Medical College and Hospital, Udaipur, Rajasthan, India.
SHASHANK KOTHARI Department of Radiation Oncology, Geetanjali Medical College and Hospital, Udaipur, Rajasthan, India

DOI:

https://doi.org/10.22159/ajpcr.2025v18i3.53921

Keywords:

TPF, Induction chemotherapy, Head-and-neck cancer.

Abstract

Objective: India has a high prevalence of locally advanced head-and-neck (H&N) cancer, with poor outcomes from concurrent chemoradiotherapy (CRT). Many centers widely practice induction chemotherapy (IC) to address this. The commonly used IC regimen with three cycles of docetaxel, cisplatin, and 5-fluorouracil (TPF) often results in poor tolerance and low compliance among Indian patients. This single arm study assess the efficacy, toxicity, and compliance of two cycles of TPF as IC followed by CRT in locally advanced H&N cancers.

Methods: We enrolled adult patients with previously untreated, non-metastatic, newly diagnosed, unresectable, and locally advanced H&N cancer planned for definitive CRT in tumor board. Patients were scheduled for IC with two cycles of TPF followed by concurrent CRT with weekly cisplatin.

Results: Between October 2022 and March 2024, we enrolled a total of 58 patients for the study. After two cycles of IC, 11 patients defaulted, and three had progressive disease. Out of the 44 patients who started CRT, 32 completed the treatment. Three patients were lost to follow-up. We observed a complete response in 27 patients (84.3%). Only two patients had residual disease, and no distant failures occurred. The treatment was well tolerated, with no cases of neutropenia. We noted grade 2 neutropenia in one patient during IC and 11 patients during CRT. Grade 3 mucositis appeared in 5 patients (15.6%) and Grade 3 dysphagia in 7 patients (21.9%).

Conclusion: Two cycles of TPF IC demonstrate good tolerance and efficacy, making them a viable option for sequential treatment of locally advanced H&N cancers in Indian settings.

Downloads

Download data is not yet available.

References

The Global Cancer Observatory. Available from: https://gco.iarc.fr/ today/data/factsheets/populations/356-india-fact-sheets.pdf [Last acceessed on 2024 Jul ].

Goswami U, Banerjee S, Dutta S, Bera A. Treatment outcome and toxicity of hypofractionated radiotherapy with concomitant chemotherapy versus conventional fractionated concomitant chemoradiation in locally advanced head-and-neck carcinoma: A comparative study. Asian J Pharm Clin Res 2022 Jul 7;15(7):167-71.

Ma J, Liu Y, Yang X, Zhang CP, Zhang ZY, Zhong LP. Induction chemotherapy in patients with resectable head and neck squamous cell carcinoma: A meta-analysis. World J Surg Oncol. 2013;11:67. doi: 10.1186/1477-7819-11-67, PMID 23497185

Vermorken JB, Remenar E, Van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357(17):1695-704. doi: 10.1056/ NEJMoa071028, PMID 17960012

Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357(17):1705-15. doi: 10.1056/NEJMoa070956, PMID 17960013

Bera A, Dutta S, Banerjee C, Banerjee S. Prevalence of serum suboptimal vitamin d3 levels and its correlation with treatment outcome, sociodemographic profile among cancer patients: A retrospective analysis. Asian J Pharm Clin Res. 2022 Aug 7;15(8):57-60.

Patil VM, Chakraborty S, Shenoy PK, Manuprasad A, Sajith Babu TP, Shivkumar T, et al. Tolerance and toxicity of neoadjuvant docetaxel, cisplatin and 5 fluorouracil regimen in technically unresectable oral cancer in resource limited rural based tertiary cancer center. Indian J Cancer. 2014 Jan-Mar;51(1):69-72. doi: 10.4103/0019-509X.134649, PMID 24947100

Patel UA, Thakkar KH, Holloway N. Patient compliance to radiation for advanced head and neck cancer at a tertiary care county hospital. Laryngoscope. 2008 Mar;118(3):428-32. doi: 10.1097/ MLG.0b013e31815ae3d2, PMID 18043491

Patel UA, Patadia MO, Holloway N, Rosen F. Poor radiotherapy compliance predicts persistent regional disease in advanced head/neck cancer. Laryngoscope. 2009;119(3):528-33. doi: 10.1002/lary.20072, PMID 19160390

Tousif D, Sarathy V, Kumar R, Naik R. Randomized controlled study comparing efficacy and toxicity of weekly vs. 3-Weekly induction chemotherapy in locally advanced head and neck squamous cell carcinoma. Front Oncol. 2020;10:1284. doi:10.3389/fonc.2020.01284, PMID 32850394

Patil VM, Noronha V, Joshi A, Muddu VK, Dhumal S, Arya S, et al. Weekly chemotherapy as Induction chemotherapy in locally advanced head and neck cancer for patients ineligible for 3 weekly maximum tolerable dose chemotherapy. Indian J Cancer. 2014 Jan- Mar;51(1):20-4. doi: 10.4103/0019-509X.134608, PMID 24947091

Aparna G, Partha N, Jaydip B. Sequential chemoradiation in locally advanced head and neck cancer after induction chemotherapy: An induction chemotherapy schedule more suited to a limited resource setting. Ecancermedicalscience. 2015;9:543. doi: 10.3332/ ecancer.2015.543, PMID 26082800

Zaheer S, Siddiqui SA, Akram M, Hasan SA. Induction chemotherapy with cisplatin and ifosfamide in locally advanced inoperable squamous cell carcinoma of the head and neck: A single-institution experience. Indian J Cancer. 2016 Jul-Sep;53(3):372-6. doi: 10.4103/0019- 509X.200661, PMID 28244461

Rehmani M, Khan IA. Monitoring of contrast agent-induced toxicity in a tertiary health-care center. Asian J Pharm Clin Res. 2024 Jun 7;17(6):29-33.

Ghi MG, Paccagnella A, D’Amanzo P, Mione CA, Fasan S, Paro S, et al. Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: A phase II feasibility study. Int J Radiat Oncol Biol Phys. 2004;59(2):481-7. doi: 10.1016/j.ijrobp.2003.10.055, PMID 15145166

Kulkarni MR. Head and neck cancer burden in India. Int J Head Neck Surg. 2013;4(1):29-35. doi: 10.5005/jp-journals-10001-1132

Fowler JF, Lindstrom MJ. Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys. 1992;23(2):457-67. doi: 10.1016/0360-3016(92)90768-d, PMID 1534082

Driessen CM, Groenewoud JM, De Boer JP, Gelderblom H, Van der Graaf WT, Prins JB, et al. Quality of life of patients with locally advanced head and neck cancer treated with induction chemotherapy followed by cisplatin-containing chemoradiotherapy in the Dutch Condor study: A randomized controlled trial. Support Care Cancer. 2018;26(4):1233-42. doi:10.1007/s00520-017-3946-7, PMID 29230548

Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, bioradiotherapy for larynx preservation: The TREMPLIN randomized phase II study. J Clin Oncol. 2013 Mar 1;31(7):853-9. doi: 10.1200/ JCO.2012.42.3988. Erratum in: J Clin Oncol. 2013 May 1;31(13):1702, PMID 23341517

Niharika D, Darisi N, Kavitha R, Konakalla A. Roles of concurrent chemo radiotherapy and radiotherapy alone in the management of malignancies of head and neck in a tertiary care hospital. Inter J Pharm Clin Res. 2023;15(9):298-304.

Lokich J, Anderson N. Carboplatin versus cisplatin in solid tumors: An analysis of the literature. Ann Oncol. 1998;9(1):13-21. doi: 10.1023/a:1008215213739, PMID 9541678

Osman N, Elamin YY, Rafee S, O’Brien C, Stassen LF, Timon C, et al. Weekly cisplatin concurrently with radiotherapy in head and neck squamous cell cancer: A retrospective analysis of a tertiary institute experience. Eur Arch Otorhinolaryngol. 2014;271:2253-9.